|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-11-30
|
|
pubmed:abstractText |
Effective chemotherapy with the least toxicity is important for patients with inoperable or advanced hepatocellular carcinoma. Single use of pegylated liposomal doxorubicin has been reported to be safe and effective with varying treatment response. The authors evaluate its activity in combination with capecitabine or gemcitabine as salvage therapy in these patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Liposomes,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/alpha-Fetoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/capecitabine,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine,
http://linkedlifedata.com/resource/pubmed/chemical/pegylated liposomal doxorubicin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1537-453X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
540-6
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16317261-Adult,
pubmed-meshheading:16317261-Aged,
pubmed-meshheading:16317261-Antibiotics, Antineoplastic,
pubmed-meshheading:16317261-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16317261-Carcinoma, Hepatocellular,
pubmed-meshheading:16317261-Deoxycytidine,
pubmed-meshheading:16317261-Doxorubicin,
pubmed-meshheading:16317261-Fatigue,
pubmed-meshheading:16317261-Female,
pubmed-meshheading:16317261-Fluorouracil,
pubmed-meshheading:16317261-Hepatitis B, Chronic,
pubmed-meshheading:16317261-Humans,
pubmed-meshheading:16317261-Liposomes,
pubmed-meshheading:16317261-Liver Neoplasms,
pubmed-meshheading:16317261-Lung Neoplasms,
pubmed-meshheading:16317261-Male,
pubmed-meshheading:16317261-Middle Aged,
pubmed-meshheading:16317261-Mucositis,
pubmed-meshheading:16317261-Neoplasm Proteins,
pubmed-meshheading:16317261-Paresthesia,
pubmed-meshheading:16317261-Polyethylene Glycols,
pubmed-meshheading:16317261-Salvage Therapy,
pubmed-meshheading:16317261-Survival Analysis,
pubmed-meshheading:16317261-Treatment Outcome,
pubmed-meshheading:16317261-Tumor Markers, Biological,
pubmed-meshheading:16317261-alpha-Fetoproteins
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
|
|
pubmed:affiliation |
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, and the National Yang-Ming University Taipei, Taiwan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
